Merck KGaA Joins Rush To Develop Toll-Like Receptor 9 Agonists
This article was originally published in The Pink Sheet Daily
Executive Summary
Company signed a deal with Idera valued at $421 million, gaining two of its lead TLR9 candidates for oncology indications, excluding vaccines.
You may also be interested in...
Idera/Merck KGaA TLR9 Misses Mark In RCC
Monotherapy fails; Merck pursuing IMO-2055 as combo therapy.
Idera/Merck KGaA TLR9 Misses Mark In RCC
Monotherapy fails; Merck pursuing IMO-2055 as combo therapy.
Anadys Resumes Work With TLR7 Drug
HCV candidate’s preclinical toxicity resolved, but investor focus is still mainly on polymerase inhibitor.